{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:36:29Z","timestamp":1789497389694,"version":"build-2803163510"},"reference-count":65,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T00:00:00Z","timestamp":1682121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Multiple myeloma (MM) is a malignant clonal plasma cell disorder in the bone marrow and is the second-most common hematologic malignancy in adults. Although patients with MM have a moderate life expectancy, it remains a heterogeneous disease that often requires multiple lines of chemotherapy for durable control and long-term survival. This review outlines current management strategies for both transplant-eligible and transplant-ineligible patients as well as for relapsed and refractory disease. Advances in drug therapies have widened management options and improved survival. In this paper, we also discuss implications for special populations and survivorship care.<\/jats:p>","DOI":"10.3390\/curroncol30050334","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T06:20:42Z","timestamp":1682317242000},"page":"4382-4401","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Management of Multiple Myeloma: A Review for General Practitioners in Oncology"],"prefix":"10.3390","volume":"30","author":[{"given":"Bethany E.","family":"Monteith","sequence":"first","affiliation":[{"name":"Department of Medicine, Queen\u2019s University, Kingston, ON K7L 3N6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9407-6265","authenticated-orcid":false,"given":"Irwindeep","family":"Sandhu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton AB T6G 1Z2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann S.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, University of Alberta, Edmonton, AB T6G 2T4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,22]]},"reference":[{"key":"ref_1","unstructured":"(2023, March 05). Myeloma\u2014Cancer Stat Facts, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"ref_2","unstructured":"Lee, S. (2023, March 07). Cancer Statistics. Available online: https:\/\/cancer.ca\/en\/research\/cancer-statistics."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent Trends in Multiple Myeloma Incidence and Survival by Age, Race, and Ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv."},{"key":"ref_4","unstructured":"(2023, March 09). Drug Formulary. Available online: https:\/\/www.cancercareontario.ca\/en\/cancer-treatments\/chemotherapy\/drug-formulary."},{"key":"ref_5","unstructured":"(2023, March 09). Cancer Drug Manual. Available online: http:\/\/www.bccancer.bc.ca\/health-professionals\/clinical-resources\/cancer-drug-manual."},{"key":"ref_6","unstructured":"CADTH (2023, March 09). Selinexor. Available online: https:\/\/www.cadth.ca\/selinexor."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.clml.2022.03.002","article-title":"Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007\u20132018: Retrospective Analysis from the Canadian Myeloma Research Group Database","volume":"22","author":"Mian","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0305-7372(10)70008-6","article-title":"Role of New Treatment Approaches in Defining Treatment Goals in Multiple Myeloma\u2014The Ultimate Goal Is Extended Survival","volume":"36","author":"Durie","year":"2010","journal-title":"Cancer Treat. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3324\/haematol.2015.127548","article-title":"Large Registry Analysis to Accurately Define Second Malignancy Rates and Risks in a Well-Characterized Cohort of 744 Consecutive Multiple Myeloma Patients Followed-up for 25 Years","volume":"100","author":"Engelhardt","year":"2015","journal-title":"Haematologica"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e052759","DOI":"10.1136\/bmjopen-2021-052759","article-title":"Clinical Features and Diagnosis of Multiple Myeloma: A Population-Based Cohort Study in Primary Care","volume":"11","author":"Seesaghur","year":"2021","journal-title":"BMJ Open."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.46747\/cfp.6704265","article-title":"Cancer Diagnosis in Primary Care: Six Steps to Reducing the Diagnostic Interval","volume":"67","author":"Wilkinson","year":"2021","journal-title":"Can. Fam. Physician"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International Staging System for Multiple Myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"JCO"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric Assessment Predicts Survival and Toxicities in Elderly Myeloma Patients: An International Myeloma Working Group Report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"35478","DOI":"10.18632\/oncotarget.26269","article-title":"The Genomic Features Associated with High-Risk Multiple Myeloma","volume":"9","author":"Walker","year":"2018","journal-title":"Oncotarget"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A High-Risk, Double-Hit, Group of Newly Diagnosed Myeloma Identified by Genomic Analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"ref_18","unstructured":"(2023, March 09). CADTH Provisional Funding Algorithms | CADTH. Available online: https:\/\/www.cadth.ca\/cadth-provisional-funding-algorithms."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1182\/blood-2016-07-726778","article-title":"Serum Free Light Chains, Not Urine Specimens, Should Be Used to Evaluate Response in Light-Chain Multiple Myeloma","volume":"128","author":"Dejoie","year":"2016","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1182\/blood-2018-99-113508","article-title":"The Real-World Frequency of 24-Hour Urine Protein Electrophoresis (UPEP), Serum Free Light Chain (SFLC), and Serum Protein Electrophoresis (SPEP) Testing in Patients with Multiple Myeloma (MM)","volume":"132","author":"Foster","year":"2018","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood-2018-99-112396","article-title":"Light Chain Escape in Multiple Myeloma","volume":"132","author":"Dejoie","year":"2018","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group Consensus Criteria for Response and Minimal Residual Disease Assessment in Multiple Myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International Uniform Response Criteria for Multiple Myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41408-022-00779-2","article-title":"The Prevalence and Outcomes of Frail Older Adults in Clinical Trials in Multiple Myeloma: A Systematic Review","volume":"13","author":"Mian","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/jgs.16919","article-title":"Health Heterogeneity in Older Adults: Exploration in the Canadian Longitudinal Study on Aging","volume":"69","author":"Nguyen","year":"2021","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/CCO.0000000000000792","article-title":"Geriatric Assessments and Frailty Scores in Multiple Myeloma Patients: A Needed Tool for Individualized Treatment?","volume":"33","author":"Gengenbach","year":"2021","journal-title":"Curr. Opin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/hematology.2022000346","article-title":"Fitness and Frailty in Myeloma","volume":"2022","author":"Pawlyn","year":"2022","journal-title":"Hematology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clml.2018.01.005","article-title":"Undertreatment of Older Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies","volume":"18","author":"Fakhri","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Lecat, C.S.Y., McCourt, O., Land, J., Yong, K., and Fisher, A. (2021). Multiple Myeloma and Physical Activity. BMC Res. Notes, 14.","DOI":"10.1186\/s13104-021-05591-y"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Morales Rodr\u00edguez, E., Lorenzo Calvo, J., Granado-Peinado, M., P\u00e9rez-Bilbao, T., and San Juan, A.F. (2022). Effects of Exercise Programs on Psychoemotional and Quality-of-Life Factors in Adult Patients with Cancer and Hematopoietic Stem Cell Transplantation or Bone Marrow Transplantation: A Systematic Review. Int. J. Environ. Res. Public. Health, 19.","DOI":"10.3390\/ijerph192315896"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/0284186X.2023.2178326","article-title":"Exercise Prehabilitation for People with Myeloma Undergoing Autologous Stem Cell Transplantation: Results from PERCEPT Pilot Randomised Controlled Trial","volume":"15","author":"McCourt","year":"2023","journal-title":"Acta Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple Myeloma Epidemiology and Survival, a Unique Malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2147\/JBM.S380133","article-title":"Risk Assessment for Newly Diagnosed Fit Young Patients with Multiple Myeloma in the Era of Novel Treatment Modalities: Should There Be Additional Factors Taken into Consideration?","volume":"13","author":"Kaloyannidis","year":"2022","journal-title":"J. Blood Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e13481","DOI":"10.1111\/ecc.13481","article-title":"Perspectives on Returning to Work of Multiple Myeloma Patients: A Qualitative Interview Study","volume":"30","author":"Bennink","year":"2021","journal-title":"Eur. J. Cancer Care"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/ejh.13298","article-title":"Productivity Losses in Patients with Newly Diagnosed Multiple Myeloma Following Stem Cell Transplantation and the Impact of Maintenance Therapy","volume":"103","author":"Jackson","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Osborne, T.R., Ramsenthaler, C., de Wolf-Linder, S., Schey, S.A., Siegert, R.J., Edmonds, P.M., and Higginson, I.J. (2014). Understanding What Matters Most to People with Multiple Myeloma: A Qualitative Study of Views on Quality of Life. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-496"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1007\/s00520-015-2644-6","article-title":"Development of a Conceptual Model to Illustrate the Impact of Multiple Myeloma and Its Treatment on Health-Related Quality of Life","volume":"23","author":"Baz","year":"2015","journal-title":"Support. Care Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2381468318814253","DOI":"10.1177\/2381468318814253","article-title":"Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making","volume":"4","author":"Dimopoulos","year":"2019","journal-title":"MDM Policy Pract."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41408-021-00432-4","article-title":"Management of Patients with Multiple Myeloma beyond the Clinical-Trial Setting: Understanding the Balance between Efficacy, Safety and Tolerability, and Quality of Life","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00001622-200201000-00006","article-title":"Multiple Myeloma: Present and Future","volume":"14","author":"Hussein","year":"2002","journal-title":"Curr. Opin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ajh.25764","article-title":"Treatment and Disease-Related Complications in Multiple Myeloma: Implications for Survivorship","volume":"95","author":"Chakraborty","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.clml.2021.07.028","article-title":"Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (Formerly Myeloma Canada Research Network) Consensus Guideline Consortium","volume":"22","author":"LeBlanc","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic Bone Disease: Clinical Features, Pathophysiology and Treatment Strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma\u2013Related Bone Disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3324\/haematol.2019.230011","article-title":"Fractures and Survival in Multiple Myeloma: Results from a Population-Based Study","volume":"105","author":"Thorsteinsdottir","year":"2020","journal-title":"Haematologica"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of Bone Disease in Multiple Myeloma: From Bench to Bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 Patients with Newly Diagnosed Multiple Myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1016\/j.clml.2020.01.017","article-title":"Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium","volume":"20","author":"Bergstrom","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1470-2045(10)70198-4","article-title":"Effect of Pamidronate 30 Mg versus 90 Mg on Physical Function in Patients with Newly Diagnosed Multiple Myeloma (Nordic Myeloma Study Group): A Double-Blind, Randomised Controlled Trial","volume":"11","author":"Gimsing","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-Line Treatment with Zoledronic Acid as Compared with Clodronic Acid in Multiple Myeloma (MRC Myeloma IX): A Randomised Controlled Trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","article-title":"Incidence, Risk Factors and Management of Osteonecrosis of the Jaw in Patients with Multiple Myeloma: A Single-Centre Experience in 303 Patients","volume":"134","author":"Zervas","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_53","first-page":"e7126982","article-title":"Incidence and Risk Factors of Osteonecrosis of Femoral Head in Multiple Myeloma Patients Undergoing Dexamethasone-Based Regimens","volume":"2020","author":"Wu","year":"2020","journal-title":"BioMed Res. Int."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.2215\/CJN.12231212","article-title":"Kidney Disease and Multiple Myeloma","volume":"8","author":"Heher","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"JCO"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple Myeloma and Infections: A Population-Based Study on 9253 Multiple Myeloma Patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus Guidelines and Recommendations for Infection Prevention in Multiple Myeloma: A Report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/S0049-3848(16)30103-7","article-title":"Update of Thrombosis in Multiple Myeloma","volume":"140","author":"Leebeek","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"101144","DOI":"10.1016\/j.beha.2020.101144","article-title":"Second Malignancies in Multiple Myeloma; Emerging Patterns and Future Directions","volume":"33","author":"Maclachlan","year":"2020","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"E1349","DOI":"10.1503\/cmaj.202824","article-title":"Managing Multiple Myeloma","volume":"193","author":"Lee","year":"2021","journal-title":"CMAJ"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/leu.2011.346","article-title":"Management of Treatment-Emergent Peripheral Neuropathy in Multiple Myeloma","volume":"26","author":"Richardson","year":"2012","journal-title":"Leukemia"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hon.2149","article-title":"Therapy-Related Peripheral Neuropathy in Multiple Myeloma Patients","volume":"33","author":"Morawska","year":"2015","journal-title":"Hematol. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41408-019-0183-y","article-title":"Management of Cardiovascular Risk in Patients with Multiple Myeloma","volume":"9","author":"Plummer","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clml.2016.11.009","article-title":"Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational, Retrospective, Cohort Study","volume":"17","author":"Kistler","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/hon.2959","article-title":"Cardiotoxicity as an Adverse Effect of Immunomodulatory Drugs and Proteasome Inhibitors in Multiple Myeloma: A Network Meta-Analysis of Randomized Clinical Trials","volume":"40","author":"Das","year":"2022","journal-title":"Hematol. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/5\/334\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:21:12Z","timestamp":1760124072000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/5\/334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,22]]},"references-count":65,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["curroncol30050334"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30050334","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,22]]}}}